Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.Journal of Medicinal Chemistry|April 23, 2008
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinaseBrian K Albrecht, Jean-Christophe Harmange, David Bauer, et al.HGG Advances|June 14, 2025
Long-Read Sequencing is Required for Precision Diagnosis of Incontinentia PigmentiMonica H Wojcik, Robin D Clark, Abdallah F Elias, et al.Research Square|February 20, 2025
Long-Read Sequencing is Required for Precision Diagnosis of Incontinentia PigmentiMonica H Wojcik, Robin D Clark, Abdallah F Elias, et al.ACS Medicinal Chemistry Letters|December 21, 2016
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target EngagementIsaac E Marx, Thomas A Dineen, Jessica Able, et al.ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement"Isaac E Marx, Thomas A Dineen, Jessica Able, et al.Bioorganic & Medicinal Chemistry Letters|June 21, 2017
The discovery of benzoxazine sulfonamide inhibitors of Na<sub>V</sub>1.7: Tools that bridge efficacy and target engagementDaniel S La, Emily A Peterson, Christiane Bode, et al.Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.ACS Chemical Biology|March 16, 2019
Engineering Na<sub>V</sub>1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance PharmacokineticsJustin K Murray, Bin Wu, Christopher M Tegley, et al.Pageof 6